Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. [3] It was discovered for the treatment of hepatitis C [4] and has since been investigated for use against other viral diseases such as AIDS and COVID-19, [2] [5] for which it was granted conditional approval in China. [6] [7] Azvudine was first discovered in 2007. [8]

2021年12月6日 · Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III...

Azvudine (FNC) has been shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but data regarding the Omicron BA.5.1.3 subvariant are lacking.

Azfudine, an oral antiviral drug independently developed in China, is a broad-spectrum RNA virus inhibitor that can inhibit recombinant HIV reverse transcriptase activity and can be combined with other drugs to treat AIDS (Acquired Immune Deficiency Syndrome).

Azvudine, or 2 -deoxy-2 -β-fluoro-4 –azidocytidine, can be characterized as a nucleoside reverse transcriptase inhibitor and has demonstrated in vitro antiviral activity, alone or in combination with other antiretroviral agents against HIV-1, HIV-2, [9] HBV, and HCV [10].

2024年12月26日 · Azvudine is an orally administered antiviral drug developed independently in China. It is a broad-spectrum RNA virus inhibitor. Initially developed for HIV, it was later repurposed for COVID-19. Azvudine, a nucleoside analogue, specifically inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, thereby blocking viral RNA synthesis .

2020年10月10日 · Nucleoside-based anti-HIV clinical candidate azvudine (FNC) for COVID-19 treatment. a SARS-COV-2 RNA structure showing a cytosine subunit; b A diagram showing the RNA replication process of...

2023年8月15日 · Azvudine is capable of inhibiting SARS-CoV-2, as well as its variants, including Alpha, Beta, Delta, and Omicron. Clinical trials have revealed its real-world effectiveness among hospitalized severely or critically ill COVID-19 patients or those with pre-existing conditions.

These findings indicate that Azvudine therapy showed substantial clinical benefits in hospitalised patients with COVID-19 and pre-existing conditions, and should be considered for this population of patients.

2020年12月23日 · Azvudine is a nucleoside reverse transcriptase inhibitor that acts against HIV, HBV, and HCV. Some studies also show that it is able to modulate the expression of proteins like P-glycoprotein (P-gp), MRP2, and BCRP; in one instance, it was also able to …